MedTrace Logo

Effects of Lignan-rich Diet on Cardiometabolic Risk Factors

NCT02987595 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2016-12-09

No results posted yet for this study

Summary

Diet plays an important role in relation to prevention of type 2 diabetes, cardiovascular disease and certain cancers. Studies have shown that diets with high whole-grain content could decrease the risk of these lifestyle related diseases and in Sweden the national dietary guidelines recommends whole-grain based instead of refined cereal products. It is, however, not clear whether whole-grain from wheat and rye share similar protective effects since there are large differences in amount and quality of dietary fibre and associated bioactive compounds. The aim of this study is to evaluate the impact of a wholegrain diet with low- or high lignan content on different cardiometabolic risk factors with the primary endpoint being blood glucose levels after 2h oral glucose tolerance test in men with metabolic syndrome or sign thereof.

Conditions

  • Metabolic Syndrome
  • Overweight
  • Central Obesity
  • Impaired Glucose Tolerance

Interventions

OTHER

Whole-grain rye, high lignan

Intervention week 1-8: 50 g rolled rye + 50 g puffs + 4 pieces of crisp bread + 70 g pasta. Additionally for intervention week 4-8: 4 lignan capsules per day

OTHER

Whole-grain wheat, low lignan

Intervention week 1-8: 100 g puffs + 4 pieces of crisp bread + 70 g pasta.

Sponsors & Collaborators

  • Swedish University of Agricultural Sciences

    lead OTHER

Principal Investigators

  • Rikard Landberg · Swedish University of Agricultural Sciences

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2016-10-31
Completion
2016-10-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02987595 on ClinicalTrials.gov